1.
New theory addresses frozen Earth paradox
GENEVA, Switzerland, Oct. 23 (UPI) -- U.S. scientists say an early trial of a multi-kinase inhibitor has shown impressive tumor shrinkage in patients with a hard-to-treat form of thyroid cancer.
Assistant Professor Pasi Janne of Harvard University Medical School and Professor Steven Sherman of the M.D. Anderson Cancer Center said the encouraging results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial.
The compound, XL184, targets cell growth and migration, as well as angiogenesis (blood vessel growth).
The clinical trial that's been initiated will test XL184 with and without erlotinib (Tarceva), a drug used to treat non-small lung, pancreatic and other cancers. XL184 is also being studied in glioblastoma.
The research was presented Thursday in Geneva, Switzerland, during a symposium organized by the European Organization for Research and Treatment of Cancer, the U.S. National Cancer Institute and the American Association for Cancer Research.
|
|
|
|
|
|
| Additional Science News Stories | |
WASHINGTON, May 31 (UPI) --
The U.S. House Thursday rejected a bill that would outlaw abortions based on gender, with abortion opponents promising to make the vote an election issue.
|
NEW YORK, May 31 (UPI) --
"Glee" stars Samuel Larsen, Cory Monteith and Naya Rivera are to serve as guest mentors on the U.S. talent competition show "The Glee Project," Oxygen said.
|
BALTIMORE, May 31 (UPI) --
U.S. astronomers are forecasting the Milky Way will have a violent collision with the neighboring Andromeda galaxy in about 4 billion years.
|
CLEVELAND, May 31 (UPI) --
Cleveland prosecutors have dropped their case against a man who was ticketed for littering when he dropped a dollar he was attempting to give a disabled person.
|
| Stories | Photos | People | Comments |
View Caption
